Safety

News

Lilly says Foundayo safety confirmed in ACHIEVE-4 trial

Eli Lilly's ACHIEVE-4 trial results for oral GLP-1 Foundayo set up a filing in diabetes, and provide safety data sought by the FDA.

News

FDA seeks safety data for Lilly's oral GLP-1 Foundayo

The FDA has laid out post-marketing safety testing requirements for Lilly's weight-loss pill Foundayo, including clinical trials.

News

FDA points to liver injury with Amgen's Tavneos

The FDA has raised the pressure on Amgen to withdraw vasculitis drug Tavneos from the market with a report linking serious side effects to the drug.

News

BioMarin halts Voxzogo trials due to safety signal

BioMarin has suspended dosing in phase 2 trials of its achondroplasia therapy Voxzogo aimed at broadening the drug's label.

News

Safety concerns prompt Ipsen to pull Tazverik from market

Ipsen is voluntarily withdrawing its EZH2 inhibitor Tazverik from sale after a clinical trial suggested a link with secondary blood cancers.

News

After phase 3 clean sweep, Roche plans oral BTK filing in MS

Roche is preparing to file for its oral multiple sclerosis drug fenebrutinib after a third phase 3 win, but could liver toxicity be a stumbling block?

Lilly says Foundayo safety confirmed in ACHIEVE-4 trial

FDA seeks safety data for Lilly's oral GLP-1 Foundayo

FDA points to liver injury with Amgen's Tavneos

BioMarin halts Voxzogo trials due to safety signal

Safety concerns prompt Ipsen to pull Tazverik from market

After phase 3 clean sweep, Roche plans oral BTK filing in MS

Norgine gets first EU approval for WHIM syndrome therapy

Discover a new era of healthcare panel engagement: Grounded ...

Safety

Editor's Picks